Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

J. Cortes, R. Digumarti, P. M. Parikh, M. Wetzler, J. H. Lipton, A. Hochhaus, A. R. Craig, A. C. Benichou, F. E. Nicolini, H. M. Kantarjian

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Medicine & Life Sciences